BE study with two different batches of the reference product [Study As­sess­ment]

posted by ElMaestro  – Denmark, 2014-12-16 10:01 (3800 d 00:20 ago) – Posting: # 14079
Views: 8,994

Dear tarak_desai,

❝ In a two period, single dose, cross over, BE study,it was observd that after completion of period-I, there was insufficient quantity of the reference product available to dose subjects in period-II. sponsor also doesnt have same batch reference product availalbe with them.


❝ can we use the different batch reference product in priod-II?

❝ and what other measures to be taken in this case?


Forgive me for saying this, I know this could be seen as a negative comment; But do you really think it is a good idea to proceed with this trial if you realise halfway through it that you have not been able to plan it well enough to have the Ref available in quantities sufficing for the number of subjects?
It sounds to me like the planning is completely off. Think about responsibilities, futile trials, drug accountability, and GCP.
(let me add: an argument of having to involve a new Ref batch to avoid the trial becoming futile strikes me as backward)

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
133 visitors (0 registered, 133 guests [including 8 identified bots]).
Forum time: 11:22 CEST (Europe/Vienna)

If you shut your door to all errors
truth will be shut out.    Rabindranath Tagore

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5